Apotea Valuation Multiples

Apotea is valued at $863M as of September 2026, a 1.1x revenue multiple. In the last 12 months, Apotea revenue was $810M and Apotea EBITDA was $58M.

Apotea Overview

About Apotea

Apotea AB (publ) is engaged in the online pharmacy with fast deliveries, good prices and a large selection. Its vision is to be tomorrow's pharmacy by constantly facilitating and simplifying for the customer.


Founded

2012

HQ

Sweden

Employees

831

Website

apotea.se

Financials (LTM)

Revenue: $810M
EBITDA: $58M

EV

$882M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Apotea Financials

Apotea reported last 12-month revenue of $810M and EBITDA of $58M.

In the same LTM period, Apotea generated $220M in gross profit, $58M in EBITDA, and $28M in net income.

Revenue (LTM)


Apotea P&L

In the most recent fiscal year, Apotea reported revenue of $727M and EBITDA of $47M.

Apotea is profitable as of last fiscal year, with gross margin of 27%, EBITDA margin of 6%, and net margin of 3%.

See analyst estimates for Apotea
LTMLast FY202320242025202620272028
Revenue$810M$727M$572M$687M$727M
Gross Profit$220M$196M$152M$188M$196M
Gross Margin27%27%27%27%27%
EBITDA$58M$47M$24M$42M$47M
EBITDA Margin7%6%4%6%6%
EBIT Margin5%4%2%4%4%
Net Profit$28M$23M$9M$23M$23M
Net Margin3%3%2%3%3%
Net Debt-$30M---

Financial data powered by Morningstar, Inc.

Apotea Stock Performance

Apotea has current market cap of $863M, and enterprise value of $882M.

Market Cap Evolution


Apotea's stock price is $8.29.

Apotea share price increased by 2.0% in the last 30 days, and decreased by 12.9% in the last year.

Apotea has an EPS (earnings per share) of $0.22.

See more trading valuation data for Apotea
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$882M$863M0.1%2.0%8.6%-12.9%$0.22

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Apotea Valuation Multiples

Apotea trades at 1.1x EV/Revenue multiple, and 15.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Apotea

EV / Revenue (LTM)


Apotea Financial Valuation Multiples

As of September 26, 2026, Apotea has market cap of $863M and EV of $882M.

Apotea has a P/E ratio of 30.5x.

LTMLast FY202320242025202620272028
EV/Revenue1.1x1.2x1.5x1.3x1.2x
EV/EBITDA15.3x19.0x37.2x21.0x19.0x
EV/EBIT23.8x28.8x74.5x32.0x28.8x
EV/Gross Profit4.0x4.5x5.8x4.7x4.5x
P/E30.5x37.4x94.4x38.2x37.4x
EV/FCF28.4x74.2x88.7x198.1x74.2x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Apotea Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Apotea Margins & Growth Rates

Apotea grew revenue by 12% and EBITDA by 29% in the last fiscal year.

In the most recent fiscal year, Apotea reported gross margin of 27%, EBITDA margin of 6%, and net margin of 3%.

See estimated margins and future growth rates for Apotea

Apotea Margins

Last FY202420252026202720282029
Gross Margin27%27%27%27%
EBITDA Margin6%6%6%7%
EBIT Margin4%4%4%5%
Net Margin3%3%3%4%
FCF Margin2%1%2%5%

Apotea Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth12%20%6%12%
Gross Profit Growth13%23%4%13%
EBITDA Growth29%77%11%29%
EBIT Growth25%133%11%25%
Net Profit Growth27%147%2%27%
FCF Growth221%(55%)167%221%

Data powered by FactSet, Inc. and Morningstar, Inc.

Apotea Operational KPIs

Apotea's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.8M for the same period.

Apotea's Rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Apotea's Rule of X is 37% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Apotea
LTMLast FY202320242025202620272028
Rule of 4017%19%---
Bessemer Rule of X31%37%---
Revenue per Employee-$0.9M---
Opex per Employee-$0.8M---
Opex to Revenue-96%25%23%96%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Boozt$837M$70M1.1x1.0x13.1x10.4x
Hepsiburada$1.7B($51M)0.4x0.3x(13.7x)24.7x
Anhui Huaren Health$818M$97M1.2x-10.0x-
Aldawaa Medical Services$1.8B$234M0.8x0.8x6.2x7.2x
Bxn Holding$770M$100M0.8x0.8x6.4x6.0x
Medplus Health Services$713M$66M1.3x1.2x13.7x14.9x
Brainbees Solutions$867M$29M1.1x1.0x33.9x24.3x
CEWE Group$1B$159M0.8x0.9x5.2x5.2x

This data is available for Pro users. Sign up to see all Apotea competitors and their valuation data.

Start Free Trial

Apotea VC Funding History

Before going public, Apotea raised $83M in total equity funding, across 3 rounds.

Last private valuation of Apotea was $420M, after raising $83M in March 2019 from Alecta.


Apotea Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Mar-19SecondaryAlecta$83M$420MApotea operates an online-only pharmacy in Sweden, founded by Pär Svärdson and Fabian Fischer who took over Familjeapoteket in 2003. In March 2019, Swedish pension fund manager Alecta acquired a 19% equity stake from existing owner AP6 for SEK 768 million ($79 million). The transaction valued Apotea at approximately SEK 4 billion ($410 million). At the time, Apotea reported yearly sales of SEK 2.7 billion ($280 million) and employed over 600 people, positioning it as Sweden's leading online pharmacy.
Apr-17SecondaryCreades--Creades bought 4.9 per cent of Apolea Holding, which in turn owned 96.5 per cent of the online pharmacy Apotea, investing a total of SEK 120.5 million. The shares were acquired from existing owners rather than issued by the company, and Creades took a seat on Apotea's board. The founder group remained the largest owner with more than 50 per cent after the transaction, with Sjatte AP-fonden and Ernstrom & C:O among the other significant shareholders.
May-16SecondaryOtiva--Apotea announced that a consortium led by the family investment company Ernstrom & C:o together with Avito founders Jonas Nordlander and Filip Engelbert had acquired 11 per cent of the shares in the online pharmacy from existing owners. Nordlander and Engelbert, who hold their private-market investments through Otiva, took roughly one percentage point of the company and Ernstrom & C:o the remainder. Neither the price nor the identity of the selling shareholders was disclosed.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Apotea

When was Apotea founded?Apotea was founded in 2012.
Where is Apotea headquartered?Apotea is headquartered in Sweden.
How many employees does Apotea have?As of today, Apotea has over 831 employees.
Is Apotea publicly listed?Yes, Apotea is a public company listed on Nasdaq Stockholm.
What is the stock symbol of Apotea?Apotea trades under APOTEA ticker.
When did Apotea go public?Apotea went public in 2024.
Who are competitors of Apotea?Apotea main competitors include Boozt, Hepsiburada, Anhui Huaren Health, Aldawaa Medical Services, Bxn Holding, Medplus Health Services, Brainbees Solutions, CEWE Group, Shu Yu Civilian Pharmacy, Yixintang Pharmaceutical.
What is the current market cap of Apotea?Apotea's current market cap is $863M.
What is the current revenue of Apotea?Apotea's last 12 months revenue is $810M.
What is the current revenue growth of Apotea?Apotea revenue growth (NTM/LTM) is 10%.
What is the current EV/Revenue multiple of Apotea?Current revenue multiple of Apotea is 1.1x.
What is the current EBITDA of Apotea?Apotea's last 12 months EBITDA is $58M.
What is Apotea's EBITDA margin?Apotea's last 12 months EBITDA margin is 7%.
What is the current EV/EBITDA multiple of Apotea?Current EBITDA multiple of Apotea is 15.3x.
What is the current FCF of Apotea?Apotea's last 12 months FCF is $31M.
What is Apotea's FCF margin?Apotea's last 12 months FCF margin is 4%.
What is the current EV/FCF multiple of Apotea?Current FCF multiple of Apotea is 28.4x.
How many companies Apotea has acquired to date?Apotea hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Apotea has invested to date?Apotea hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Apotea

Lists including Apotea

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial